The Right Order of Operations for Clinician-Founders
Clinician-founders should not treat evidence, reimbursement and distribution as separate workstreams; the right sequence turns clinical insight into a financeable, purchasable and adoptable business.
Start with the economic job, not the clinical grievance
Clinician-founders usually begin with a real problem because they have lived inside it: a missed diagnosis, a delayed referral, a dangerous handoff, a wasteful procedure, a patient who deteriorates after discharge. That authenticity is valuable, but it is not yet a company. The first sequencing decision is to translate the clinical grievance into an economic job that a specific stakeholder is already under pressure to solve.
A hospital does not buy fewer complications in the abstract. It buys reduced length of stay, avoided readmissions, lower labor intensity, higher throughput, reduced malpractice exposure, better documentation, or service-line growth. A payer does not buy better engagement; it buys lower medical loss ratio, risk adjustment accuracy, network performance, Star ratings, or avoidance of high-cost events. A physician group may buy time, capacity, referral retention, or contract performance. The same clinical problem can map to different economic jobs, and the choice determines the rest of the company.
This is where many clinician-founders sequence incorrectly. They build evidence around what clinicians find interesting, then search for reimbursement and distribution later. Instead, they should define the initial use case by asking: who has budget authority, what financial metric moves within an observable time frame, and what operational behavior must change for value to appear? Evidence, reimbursement and distribution are not independent lanes; they are consequences of this first strategic choice. If the economic job is vague, every later milestone becomes more expensive and less persuasive.
Design evidence for the next buyer decision, not for scientific completeness
Evidence should be staged. The first evidence package does not need to answer every question a guideline committee or national payer might ask. It needs to reduce the uncertainty held by the next decision-maker in the sequence. For an early hospital pilot, that may mean technical feasibility, clinician usability, safety, and a credible operational leading indicator. For a payer contract, it may mean claims-based cost offsets, defined eligible population, and attribution logic. For FDA clearance, it may mean analytical validity, clinical validation, and risk controls. Confusing these audiences leads to overbuilt studies that consume capital without unlocking adoption.
Clinician-founders often have an understandable bias toward prospective, peer-reviewed, clinically elegant studies. Those can matter, especially for diagnostic, therapeutic and AI-enabled products that influence clinical decisions. But the mechanism of commercial adoption usually requires more than clinical accuracy. A sepsis tool with strong AUC but poor alert acceptance fails distribution. A remote monitoring model that identifies risk but creates uncompensated nurse work fails unit economics. A surgical device that shortens operative time but disrupts preference cards and training may stall despite a statistically significant endpoint.
The right sequencing is to build a ladder of evidence. The bottom rung is problem validation with workflow and baseline economics. The next rung is product performance in the intended setting. Then comes operational impact: time saved, avoided utilization, increased capacity, better coding, or improved adherence. Only after those are credible should the company invest heavily in broader comparative effectiveness or multi-site outcomes studies. This is not a case against rigorous evidence. It is a case for matching rigor to the decision being sought, so each study buys a specific option: pilot conversion, procurement approval, payer negotiation, regulatory progress, or enterprise expansion.
Reimbursement strategy begins with who pays today
Reimbursement is frequently treated as a future milestone: first build product, then generate evidence, then obtain a code or payer policy. That may work for some categories, but it is dangerous as a default. Reimbursement strategy starts by understanding how the relevant activity is paid for today, who captures the revenue, who bears the cost, and whether the product changes that balance. A technology can be clinically useful and still commercially stranded if it improves outcomes for one party while imposing cost or work on another.
There are several reimbursement paths, each with different implications. A product may be covered under existing CPT, HCPCS, DRG, APC, or remote monitoring codes. It may be sold as an enterprise expense justified by value-based contracts. It may require a new code, payer policy, or technology add-on payment. It may be bundled into provider economics, employer benefits, or pharma support programs. These are not interchangeable routes. Existing codes can accelerate adoption but often come with documentation burden, utilization limits, and margin pressure. New codes can create durable economics but require time, evidence, society support, and payer acceptance. Enterprise value-based sales can be powerful but depend on attribution, data access, and willingness to take risk.
The practical question is not simply, “Can this be reimbursed?” It is, “Can someone be paid enough, soon enough, with low enough administrative friction, to adopt this at scale?” Clinician-founders should model reimbursement before finalizing the product wedge. If the product depends on physician billing, workflow must support documentation and compliant supervision. If it depends on hospital cost savings, the evidence must quantify avoidable expense within the budgeting cycle. If it depends on payer savings, the company must identify eligible members, engage providers, and survive actuarial scrutiny. Reimbursement is not a billing appendix; it is a design constraint.
Distribution is a workflow problem before it is a sales problem
Healthcare distribution is constrained by trust, workflow, procurement, data integration, compliance and local politics. A founder may secure an enthusiastic clinical champion and still fail because IT is overloaded, nursing leadership is unconvinced, contracting takes nine months, or the product creates work for people who were not in the sales conversation. The most common distribution mistake is to confuse clinical enthusiasm with deployability.
Distribution should therefore be designed from the point of use backward. Who opens the product? At what moment in the care pathway? What data must already be available? What task is removed, replaced or added? Who is accountable when the recommendation is wrong or ignored? What happens during nights, weekends and staff turnover? The more a product depends on behavior change by scarce labor, the stronger the evidence and incentives must be. In a labor-constrained system, even small workflow burdens can kill adoption.
This is why the sequencing of distribution must run alongside evidence, but not behind it. Early pilots should test not only outcomes but also installation time, integration requirements, training burden, alert fatigue, handoff patterns and support costs. A distribution channel is economically viable only if gross margin survives implementation and customer success. For clinician-founders, the lesson is plain: do not sell a clinical promise that requires an operational miracle. Build the product and evidence around the pathway that can actually be deployed by the buyer you intend to serve.
Use the wedge to align evidence, payment and channel
The initial wedge is the smallest commercially coherent use case, not the smallest feature. A good wedge concentrates the population, buyer, evidence endpoint, reimbursement logic and distribution motion into a tractable package. For example, a broad “cardiology AI platform” is hard to finance, validate and sell. A tool that reduces avoidable echocardiograms in a defined outpatient referral pathway has a clearer buyer, baseline, intervention, savings mechanism and channel. Narrowing is not a lack of ambition; it is how healthcare companies create proof that can travel.
A strong wedge has several properties. The clinical event is frequent enough to matter but specific enough to measure. The decision-maker is identifiable. The user is reachable. The value appears inside a budget cycle or contract year. The evidence endpoint is credible to the buyer. The reimbursement or savings mechanism is available without waiting five years. The implementation burden is proportionate to the expected return. If any one of these elements is missing, the wedge may still be scientifically interesting, but it is commercially weak.
The wedge also disciplines capital allocation. A seed-stage company should not fund a national outcomes trial, a complex enterprise salesforce and a reimbursement campaign all at once unless the category demands it and the balance sheet supports it. More often, the right order is to prove workflow and performance in one setting, convert that into economic evidence, use that evidence to secure repeatable contracts, and then expand indications, sites of care or payer arrangements. Sequencing does not mean moving slowly. It means making each milestone increase the probability and value of the next.
Investors should underwrite sequence risk, not just market size
Institutional investors often assess medtech and healthtech opportunities through market size, founder-market fit, regulatory path, evidence quality and early customer interest. Those factors matter, but they miss a central risk: whether the company has chosen an order of operations that can be financed. A large market with a mis-sequenced plan can be worse than a smaller wedge with tight alignment among evidence, reimbursement and distribution. The former absorbs capital while waiting for external systems to change; the latter creates leverage.
A useful diligence question is: what must be true before the next dollar becomes cheaper? If the answer is a randomized trial before any buyer can act, the financing plan must support that. If the answer is payer coverage before providers will adopt, the company needs a policy and evidence strategy early. If the answer is enterprise integration before outcomes can be shown, the investor should scrutinize implementation cost and sales cycle duration. Sequence risk shows up as long time-to-revenue, ambiguous proof points, pilots that never convert, and customers who praise the product but cannot pay for it.
For clinician-founders, the operating principle is to earn the right to broaden. Start with the economic job. Build evidence for the next decision. Choose a reimbursement path that matches current payment reality. Test distribution as workflow, not just procurement. Select a wedge that binds these pieces together. Then expand when the mechanism is proven. The companies that endure are rarely those with the most sweeping initial vision. They are the ones that turn clinical insight into a sequence of decisions that buyers, payers, users and investors can each rationally say yes to.
